- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 02.11. | Inovio stock rises 2.5-fold on plasmid DNA drug approval | ||
| 30.10. | Aspen, Bambusa close IPOs as Corxel takes SPAC route | ||
| 30.10. | Sanofi eyeing pipeline deals ahead of Dupixent patent loss | ||
| 30.10. | AZ seeking $1.5bn in annual savings by end-2029 | ||
| 29.10. | Flagship joins three biotechs together to form Etcelera | ||
| 29.10. | Dren Bio pockets $350m for rare blood cancer programme | ||
| 29.10. | US gives $99m for Ebola jab project, as cases spread in Africa | ||
| 29.10. | Lilly's tirzepatide juggernaut is still gathering momentum | ||
| 29.10. | Oura smart ring to be used in weight-loss outcomes trial | ||
| 29.10. | HHS doubles down on controversial peptides plan | ||
| 29.10. | UK budget includes £1bn biopharma investment package | ||
| 28.10. | Astellas pays $285m for Audax cancer drug, and other deals | ||
| 28.10. | GSK shares come under pressure from weaker vaccine sales | ||
| 28.10. | Lilly's triple G overpowers Ozempic in diabetes trial | ||
| 28.10. | AbbVie bids to join the BCMA crowd with etentamig | ||
| 28.10. | US MCT8 deficiency patients get 1st drug as Emcitate debuts | ||
| 27.10. | Ferring builds in reproductive health via $1.38bn Gameto buy | ||
| 27.10. | Novartis takes $1.9bn hit from Avidity takeover in Q3 | ||
| 27.10. | Anthropic sets out its biopharma ambitions in IPO doc | ||
| 27.10. | ESMO26: Ris-rez offers hope of osteosarcoma breakthrough | ||
| 27.10. | Judge backs Lilly in Novo lawsuit over weight-loss drug ads | ||
| 26.10. | Bayer gets first approval for stroke drug asundexian | ||
| 26.10. | ESMO26: AZ's claudin ADC doubles survival in GI cancers | ||
| 26.10. | UK biotech financing shoots up, setting up "a record year" | ||
| 26.10. | ESMO26: Roche's KRAS drug tops approved drugs in NSCLC |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.